SIGLEC1 Gene

Overview

flowchart TD
    SIGLEC1["SIGLEC1"] -->|"therapeutic target"| Diabetes["Diabetes"]
    SIGLEC1["SIGLEC1"] -->|"therapeutic target"| Als["Als"]
    SIGLEC1["SIGLEC1"] -->|"therapeutic target"| Atherosclerosis["Atherosclerosis"]
    SIGLEC1["SIGLEC1"] -->|"therapeutic target"| Aging["Aging"]
    SIGLEC1["SIGLEC1"] -->|"therapeutic target"| Ms["Ms"]
    SIGLEC1["SIGLEC1"] -->|"therapeutic target"| SPR["SPR"]
    SIGLEC1["SIGLEC1"] -->|"therapeutic target"| APOE["APOE"]
    SIGLEC1["SIGLEC1"] -->|"associated with"| MAPK10["MAPK10"]
    SIGLEC1["SIGLEC1"] -->|"therapeutic target"| Jak_Stat["Jak-Stat"]
    SIGLEC1["SIGLEC1"] -->|"therapeutic target"| Nf__b["Nf-Kappab"]
    SIGLEC1["SIGLEC1"] -->|"associated with"| Mapk["Mapk"]
    SIGLEC1["SIGLEC1"] -->|"therapeutic target"| DIABETES_MELLITUS["DIABETES MELLITUS"]
    SIGLEC1["SIGLEC1"] -->|"therapeutic target"| GENES["GENES"]
    SIGLEC1["SIGLEC1"] -->|"co discussed"| SORL1["SORL1"]
    style SIGLEC1 fill:#4fc3f7,stroke:#333,color:#000

SIGLEC1 (Sialic Acid-Binding Ig-Like Lectin 1), also known as CD169, Sialoadhesin, or Siglec-1, encodes a cell surface receptor belonging to the siglec family of sialic acid-binding lectins. Originally identified as a marker for activated macrophages, SIGLEC1 plays critical roles in immune recognition, cell-cell interactions, and the clearance of pathogens. More recently, SIGLEC1 has emerged as a significant factor in neurodegenerative disease pathogenesis through its involvement in neuroinflammation, amyloid-beta clearance, and immune modulation in the brain.

SIGLEC1 is expressed primarily on monocytes and macrophages throughout the body, including in the brain where it marks a specific subset of macrophages with distinct functional properties. Its ability to recognize sialylated glycans on host cells and pathogens makes it a unique interface between innate immunity and tissue homeostasis. In neurodegenerative diseases like Alzheimer’s and Parkinson’s, SIGLEC1-expressing macrophages may influence disease progression through their roles in clearing or potentially propagating pathological proteins.

Gene Information

Protein Structure

Domain Architecture

SIGLEC1 possesses a characteristic siglec structure:

1. Extracellular Domain:

   • N-terminal V-type Ig domain: Contains the sialic acid-binding site

   • C2-type Ig domains (16 repeats): Form the stalk region

   • Mucin-like region: Provides extended structure

2. Transmembrane Domain:

   • Single transmembrane helix: Anchors the protein in the plasma membrane

   • Basic residue motif: Important for membrane association

3. Cytoplasmic Domain:

   • Immunoreceptor Tyrosine-based Inhibition Motifs (ITIMs): Two ITIM sequences

   • Signaling capacity: Recruits phosphatases for signal modulation

Structural Features

• Sialic acid binding: The N-terminal domain specifically recognizes α2,3-linked and α2,6-linked sialic acids

• Extended structure: The mucin-like region extends the ligand-binding domain away from the cell surface

• ITIM signaling: Provides inhibitory signaling capacity

Normal Function

Immune Recognition

SIGLEC1 serves multiple immune functions:

1. Sialic Acid Recognition: Binds to sialylated glycans on host cells and pathogens

2. Phagocyte Receptor: Mediates binding to sialylated ligands on target cells

3. Immune Regulation: Modulates inflammatory responses in macrophages and microglia

4. Cell Adhesion: Facilitates cell-cell interactions in immune tissues

5. Pathogen Clearance: Recognizes sialylated patterns on microbes

Signaling Mechanisms

SIGLEC1 transduces signals through its cytoplasmic tail:

1. ITIM Motifs: Contain immunoreceptor tyrosine-based inhibition sequences

2. Phosphatase Recruitment: ITIMs recruit SHP-1 and SHP-2 phosphatases

3. Modulation of Activation: Lowers immune cell activation thresholds

4. Anti-inflammatory Effects: Can suppress excessive immune responses

Tissue Distribution

SIGLEC1 shows specific expression patterns:

• Spleen: Highest expression in marginal zone macrophages

• Lymph Nodes: Expressed on subcapsular sinus macrophages

• Bone Marrow: Present on specific macrophage subsets

• Brain: Expressed on activated microglia in disease states

Role in Neurodegenerative Diseases

Alzheimer’s Disease

SIGLEC1 has significant implications for AD pathogenesis:

1. Microglial Activation: SIGLEC1 marks a specific activated microglial population in AD brain. These CD169+ microglia cluster around amyloid plaques and represent a disease-associated state.

2. Amyloid-beta Binding: SIGLEC1 can bind to amyloid-beta peptides, potentially facilitating their clearance by macrophages. The sialic acid-binding property may be involved in Aβ recognition.

3. Neuroinflammation: SIGLEC1+ macrophages produce pro-inflammatory cytokines that contribute to chronic neuroinflammation. The balance between protective clearance and harmful inflammation remains under investigation.

4. Expression Correlation: SIGLEC1 expression correlates with disease severity and plaque burden. Higher levels are seen in more advanced disease stages.

5. Therapeutic Target: Targeting SIGLEC1 represents a potential approach to modulate microglial function in AD.

Parkinson’s Disease

SIGLEC1 connections to PD include:

1. Neuroinflammation: SIGLEC1+ macrophages are present in PD brain and contribute to dopaminergic neuron loss. These cells are found in the substantia nigra and other affected regions.

2. Alpha-synuclein Clearance: Evidence suggests SIGLEC1 may be involved in α-synuclein clearance mechanisms. Macrophages can take up α-synuclein, and SIGLEC1 may participate in this process.

3. Peripheral Inflammation: SIGLEC1 expression on peripheral monocytes is altered in PD. This may reflect systemic inflammatory changes in the disease.

4. Disease Progression: SIGLEC1 expression levels may correlate with disease progression and severity.

Multiple Sclerosis

SIGLEC1 plays multiple roles in MS:

1. Demyelination: SIGLEC1+ macrophages are involved in myelin clearance in active lesions. They phagocytose myelin debris in evolving demyelinating lesions.

2. Inflammatory Lesions: High SIGLEC1 expression in MS lesions correlates with active inflammation. The CD169+ macrophage population is prominent in acute and chronic active lesions.

3. Biomarker Potential: Cerebrospinal fluid SIGLEC1 levels may serve as a disease activity marker. Elevated levels correlate with clinical exacerbations.

4. Therapeutic Target: Modulating SIGLEC1+ macrophage function may reduce demyelination and promote repair.

HIV-Associated Neurocognitive Disorder (HAND)

SIGLEC1 is implicated in HIV neuropathogenesis:

1. Viral Entry: SIGLEC1 can mediate HIV binding to macrophages, facilitating viral entry into these cells. This represents a mechanism for viral reservoirs in the brain.

2. Neuroinflammation: SIGLEC1+ macrophages contribute to chronic neuroinflammation in HIV. These cells produce inflammatory mediators that affect neuronal function.

3. Cognitive Decline: SIGLEC1 expression correlates with cognitive impairment in HIV patients. Higher levels are associated with more severe neurocognitive deficits.

Molecular Mechanisms

Sialic Acid Recognition

SIGLEC1 binding involves:

1. Sialylated Ligands: Recognizes specific sialylated glycoconjugates

2. Glycan Specificity: Prefers certain sialyl linkages (α2,3 and α2,6)

3. Pattern Recognition: Can distinguish between self and non-self sialylation

Signal Transduction

ITIM-mediated signaling includes:

1. Tyrosine Phosphorylation: ITIM tyrosines become phosphorylated upon ligand binding

2. Phosphatase Recruitment: SHP-1 and SHP-2 are recruited to phosphorylated ITIMs

3. Signaling Inhibition: Phosphatase activity dampens activating signals

4. Immunomodulation: Overall effect is to modulate immune cell activation

Protein Interactions

SIGLEC1 interacts with:

• Sialylated proteins: Various sialylated targets

• SHP-1/SHP-2: Phosphatases for signal transduction

• Amyloid-beta: Direct binding in AD

• Alpha-synuclein: Potential interaction in PD

• Viral proteins: HIV gp120 binding

Expression and Localization

Brain Expression

SIGLEC1 shows disease-specific brain expression:

• Healthy Brain: Very low or undetectable expression

• Alzheimer’s Disease: High expression in plaque-associated microglia

• Parkinson’s Disease: Present in substantia nigra and other regions

• Multiple Sclerosis: High expression in active demyelinating lesions

• HIV Brain: Elevated expression in infected individuals

Cell-Type Expression

• Microglia: Activated microglia upregulate SIGLEC1

• Macrophages: Primary expressors in peripheral tissues

• Monocytes: Express SIGLEC1 upon activation

• Dendritic Cells: Some subsets express SIGLEC1

Therapeutic Implications

Target Rationale

SIGLEC1-based therapies may address:

1. Modulate Neuroinflammation: Reduce harmful inflammation while preserving beneficial functions

2. Enhance Clearance: Promote clearance of pathological proteins

3. Block Viral Entry: Prevent HIV infection of macrophages in CNS

Therapeutic Approaches

1. Monoclonal Antibodies: Anti-SIGLEC1 antibodies for immunomodulation

2. Small Molecule Inhibitors: Sialic acid analogs as competitive inhibitors

3. CAR-T Cells: SIGLEC1 as target for cell-based therapy

4. Gene Therapy: Modulating SIGLEC1 expression

Biomarker Potential

• CSF SIGLEC1: Cerebrospinal fluid levels as disease activity marker

• Peripheral Expression: Blood monocyte SIGLEC1 as biomarker

• Imaging: PET ligands for SIGLEC1 expression (in development)

Research Tools

Animal Models

• SIGLEC1 Transgenic Mice: For studying macrophage function

• Humanized Models: For HIV-related studies

Experimental Approaches

• Flow Cytometry: Identify SIGLEC1+ cell populations

• Immunohistochemistry: Localize SIGLEC1 in tissues

• Functional Assays: Study phagocytosis and signaling

Future Directions

Understanding SIGLEC1 will help:

1. Elucidate Neuroinflammation: Mechanisms of macrophage-mediated neuroinflammation

2. Develop Therapeutics: Target SIGLEC1 for neurodegenerative disease treatment

3. Identify Biomarkers: Develop diagnostic and prognostic markers

4. Understand Immune Regulation: Basic mechanisms of siglec-mediated immunity

See Also

• SIGLEC1 Protein

• Alzheimer’s Disease

• Parkinson’s Disease

• Multiple Sclerosis

• Microglia

• Neuroinflammation

• Siglec Family

Allen Brain Atlas Data

Gene Expression

• Allen Human Brain Atlas: SIGLEC1

• Allen Mouse Brain Atlas: SIGLEC1

• BrainSpan: SIGLEC1 developmental expression

External Links

• NCBI Gene: SIGLEC1

• UniProt: Q9PMN3

• Ensembl: ENSG00000105550

• OMIM: 600738